Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease

Psychopharmacology (Berl). 2022 Nov;239(11):3633-3656. doi: 10.1007/s00213-022-06238-x. Epub 2022 Sep 30.

Abstract

Rationale: The pharmacological effects of antidepressants in modulating noradrenergic transmission as compared to serotonergic transmission in a rat model of Parkinson's disease under chronic L-DOPA therapy are insufficiently explored.

Objectives: The aim of the present study was to investigate the effect of the tricyclic antidepressant desipramine administered chronically alone or jointly with L-DOPA, on motor behavior and monoamine metabolism in selected brain structures of rats with the unilateral 6-OHDA lesion.

Methods: The antiparkinsonian activities of L-DOPA and desipramine were assessed behaviorally using a rotation test and biochemically based on changes in the tissue concentrations of noradrenaline, dopamine and serotonin and their metabolites, evaluated separately for the ipsi- and contralateral motor (striatum, substantia nigra) and limbic (prefrontal cortex, hippocampus) structures of rat brain by HPLC method.

Results: Desipramine administered alone did not induce rotational behavior, but in combination with L-DOPA, it increased the number of contralateral rotations more strongly than L-DOPA alone. Both L-DOPA and desipramine + L-DOPA significantly increased DA levels in the ipsilateral striatum, substantia nigra, prefrontal cortex and the ipsi- and contralateral hippocampus. The combined treatment also significantly increased noradrenaline content in the ipsi- and contralateral striatum, while L-DOPA alone decreased serotonin level on both sides of the hippocampus.

Conclusions: The performed analysis of the level of monoamines and their metabolites in the selected brain structures suggests that co-modulation of noradrenergic and dopaminergic transmission in Parkinson's disease by the combined therapy with desipramine + L-DOPA may have some positive implications for motor and psychiatric functions but further research is needed to exclude potential negative effects.

Keywords: Contralateral rotations; Depressive-like behavior; Desipramine; L-DOPA; Monoamine levels; Unilateral 6-OHDA lesion.

MeSH terms

  • Animals
  • Antidepressive Agents, Tricyclic / pharmacology
  • Antiparkinson Agents / metabolism
  • Antiparkinson Agents / pharmacology
  • Antipruritics / metabolism
  • Antipruritics / pharmacology
  • Corpus Striatum
  • Desipramine / pharmacology
  • Dopamine / metabolism
  • Levodopa* / pharmacology
  • Norepinephrine / metabolism
  • Oxidopamine
  • Parkinson Disease* / drug therapy
  • Platelet Aggregation Inhibitors / metabolism
  • Platelet Aggregation Inhibitors / pharmacology
  • Rats
  • Serotonin / metabolism

Substances

  • Levodopa
  • Oxidopamine
  • Antidepressive Agents, Tricyclic
  • Desipramine
  • Dopamine
  • Serotonin
  • Antipruritics
  • Platelet Aggregation Inhibitors
  • Antiparkinson Agents
  • Norepinephrine